Fabio Morandi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3759984/publications.pdf

Version: 2024-02-01

all docs

109321 161849 3,378 89 35 54 citations h-index g-index papers 91 91 91 4910 docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Soluble HLA-G: Are they clinically relevant?. Seminars in Cancer Biology, 2007, 17, 469-479.	9.6	167
2	Binding of HLA-G to ITIM-Bearing Ig-like Transcript 2 Receptor Suppresses B Cell Responses. Journal of Immunology, 2014, 192, 1536-1546.	0.8	137
3	Immunogenicity of Human Mesenchymal Stem Cells in HLA-Class I-Restricted T-Cell Responses Against Viral or Tumor-Associated Antigens. Stem Cells, 2008, 26, 1275-1287.	3.2	134
4	CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma. Frontiers in Immunology, 2018, 9, 2722.	4.8	124
5	CD56brightCD16â°' NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation. Journal of Immunology, 2015, 195, 965-972.	0.8	111
6	Recent Advances in Our Understanding of HLA-G Biology: Lessons from a Wide Spectrum of Human Diseases. Journal of Immunology Research, 2016, 2016, 1-14.	2.2	104
7	Human Neuroblastoma Cells Trigger an Immunosuppressive Program in Monocytes by Stimulating Soluble HLA-G Release. Cancer Research, 2007, 67, 6433-6441.	0.9	100
8	NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model. Cells, 2015, 4, 520-537.	4.1	99
9	Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene, 2005, 24, 4634-4644.	5.9	92
10	PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Oncolmmunology, 2016, 5, e1064578.	4.6	91
11	Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model. Oncolmmunology, 2018, 7, e1378843.	4.6	88
12	A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation. Oncotarget, 2015, 6, 25602-25618.	1.8	79
13	Mechanisms of immune evasion of human neuroblastoma. Cancer Letters, 2005, 228, 155-161.	7.2	76
14	Interactions between HLA-G and HLA-E in Physiological and Pathological Conditions. Frontiers in Immunology, 2014, 5, 394.	4.8	74
15	Emerging topics and new perspectives on HLA-G. Cellular and Molecular Life Sciences, 2011, 68, 433-451.	5.4	69
16	Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma. Cancer Research, 2010, 70, 9816-9826.	0.9	65
17	Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells. Blood, 2011, 118, 5840-5850.	1.4	65
18	Immunosuppressive Microenvironment in Neuroblastoma. Frontiers in Oncology, 2013, 3, 167.	2.8	61

#	Article	IF	CITATIONS
19	Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD ⁺ . Oncolmmunology, 2018, 7, e1458809.	4.6	59
20	Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. Arthritis Research, 2004, 7, R256.	2.0	56
21	CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy. Frontiers in Immunology, 2019, 10, 760.	4.8	56
22	CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies. Cells, 2019, 8, 1527.	4.1	56
23	Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on $\hat{I}^3\hat{I}^{\prime}$ T and NK Cells. Cells, 2020, 9, 1757.	4.1	53
24	HLA-G in organ transplantation: towards clinical applications. Cellular and Molecular Life Sciences, 2011, 68, 397-404.	5 . 4	52
25	CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunology, Immunotherapy, 2008, 57, 541-548.	4.2	50
26	Immunogenicity of Human Neuroblastoma. Annals of the New York Academy of Sciences, 2004, 1028, 69-80.	3.8	48
27	Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. Leukemia, 2012, 26, 1365-1374.	7.2	48
28	Canonical and non-canonical adenosinergic pathways. Immunology Letters, 2019, 205, 25-30.	2.5	48
29	Mechanisms of the Antitumor Activity of Human $\hat{V^{3}9}\hat{V^{2}}$ T Cells in Combination With Zoledronic Acid in a Preclinical Model of Neuroblastoma. Molecular Therapy, 2013, 21, 1034-1043.	8.2	47
30	Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Annals of the New York Academy of Sciences, 2015, 1335, 10-22.	3.8	47
31	A Novel Mechanism of Soluble HLA-G Mediated Immune Modulation: Downregulation of T Cell Chemokine Receptor Expression and Impairment of Chemotaxis. PLoS ONE, 2010, 5, e11763.	2.5	43
32	Tumor mRNA-Transfected Dendritic Cells Stimulate the Generation of CTL That Recognize Neuroblastoma-Associated Antigens, Kill Tumor Cells: Immunotherapeutic Implications. Neoplasia, 2006, 8, 833-842.	5. 3	42
33	Interleukin-27 and interleukin-23 modulate human plasmacell functions. Journal of Leukocyte Biology, 2011, 89, 729-734.	3.3	40
34	Bone Marrow-Infiltrating Human Neuroblastoma Cells Express High Levels of Calprotectin and HLA-G Proteins. PLoS ONE, 2012, 7, e29922.	2,5	40
35	HLA-G and HLA-E in patients with juvenile idiopathic arthritis. Rheumatology, 2011, 50, 966-972.	1.9	38
36	The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases. Mediators of Inflammation, 2018, 2018, 1-10.	3.0	38

#	Article	IF	CITATIONS
37	Expression and Functional Analysis of Human Leukocyte Antigen Class I Antigen-Processing Machinery in Medulloblastoma. Cancer Research, 2007, 67, 5471-5478.	0.9	33
38	Interferonâ€gamma and ILâ€10 may protect from allergic polysensitization in children: preliminary evidence. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 740-742.	5.7	30
39	Plasma Levels of Soluble HLA-E and HLA-F at Diagnosis May Predict Overall Survival of Neuroblastoma Patients. BioMed Research International, 2013, 2013, 1-9.	1.9	30
40	Intrathecal Soluble HLA-E Correlates with Disease Activity in Patients with Multiple Sclerosis and may Cooperate with Soluble HLA-G in the Resolution of Neuroinflammation. Journal of Neurolmmune Pharmacology, 2013, 8, 944-955.	4.1	29
41	The emerging role of soluble HLA-G in the control of chemotaxis. Cytokine and Growth Factor Reviews, 2014, 25, 327-335.	7.2	29
42	Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells. Oncolmmunology, 2019, 8, e1574198.	4.6	29
43	Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma. Cancer Letters, 2008, 261, 235-243.	7.2	26
44	Evaluation of bone marrow as a metastatic site of human neuroblastoma. Annals of the New York Academy of Sciences, 2015, 1335, 23-31.	3.8	25
45	Close Interactions between Mesenchymal Stem Cells and Neuroblastoma Cell Lines Lead to Tumor Growth Inhibition. PLoS ONE, 2012, 7, e48654.	2.5	23
46	T cell mediated immune responses toÂToxoplasmaÂgondii inÂpregnant women with primary toxoplasmosis. Microbes and Infection, 2006, 8, 552-560.	1.9	22
47	Bone marrow of neuroblastoma patients shows downregulation of <i>CXCL12</i> expression and presence of <i>IFN</i> signature. Pediatric Blood and Cancer, 2012, 59, 44-51.	1.5	22
48	Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients. Cancer Immunology, Immunotherapy, 2011, 60, 1485-1495.	4.2	21
49	IL-27 in Human Secondary Lymphoid Organs Attracts Myeloid Dendritic Cells and Impairs HLA Class I–Restricted Antigen Presentation. Journal of Immunology, 2014, 192, 2634-2642.	0.8	20
50	Catastrophic relapse of Evans syndrome five years after allogeneic BMT notwithstanding full donor chimerism. Terminal hemolytic-uremic syndrome. Autoimmunity, 2006, 39, 505-511.	2.6	19
51	Human Amnion Epithelial Cells Impair T Cell Proliferation: The Role of HLA-G and HLA-E Molecules. Cells, 2020, 9, 2123.	4.1	19
52	HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies. International Journal of Molecular Sciences, 2022, 23, 2925.	4.1	19
53	Human <scp>TCR</scp> î³Î´ ⁺ <scp>T</scp> cells represent a novel target for <scp>IL</scp> â€27 activity. European Journal of Immunology, 2012, 42, 1547-1552.	2.9	18
54	Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future. Vaccines, 2021, 9, 43.	4.4	18

#	Article	IF	CITATIONS
55	IL-27 Driven Upregulation of Surface HLA-E Expression on Monocytes Inhibits IFN- <mml:math id="M1" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi mathvariant="bold-italic">ĵ³</mml:mi></mml:mrow></mml:math> Release by Autologous NK Cells. lournal of Immunology Research. 2014. 2014. 1-7.	2.2	17
56	CD4 ⁺ CD25 ^{hi} CD127 ^{â^'} Treg and CD4 ⁺ CD45R0 ⁺ CD49b ⁺ LAG3 ⁺ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma. Oncolmmunology, 2016, 5, e1249553.	4.6	17
57	The Circular Life of Human CD38: From Basic Science to Clinics and Back. Molecules, 2020, 25, 4844.	3.8	17
58	MYCN: from oncoprotein to tumor-associated antigen. Frontiers in Oncology, 2012, 2, 174.	2.8	16
59	IL-10 and ARG-1 Concentrations in Bone Marrow and Peripheral Blood of Metastatic Neuroblastoma Patients Do Not Associate with Clinical Outcome. Journal of Immunology Research, 2015, 2015, 1-9.	2.2	16
60	Molecular dynamics of targeting CD38 in multiple myeloma. British Journal of Haematology, 2021, 193, 581-591.	2.5	16
61	The Key Role of NAD+ in Anti-Tumor Immune Response: An Update. Frontiers in Immunology, 2021, 12, 658263.	4.8	16
62	Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells. Blood, 2015, 126, 1849-1849.	1.4	16
63	Antibody mimicry, receptors and clinical applications. Human Antibodies, 2017, 25, 75-85.	1.5	15
64	The Olive Leaves Extract Has Anti-Tumor Effects against Neuroblastoma through Inhibition of Cell Proliferation and Induction of Apoptosis. Nutrients, 2021, 13, 2178.	4.1	15
65	Ectonucleotidase Expression on Human Amnion Epithelial Cells: Adenosinergic Pathways and Dichotomic Effects on Immune Effector Cell Populations. Journal of Immunology, 2019, 202, 724-735.	0.8	13
66	Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma. Oncotarget, 2017, 8, 53194-53209.	1.8	13
67	Deregulation of focal adhesion pathway mediated by miR-659-3p is implicated in bone marrow infiltration of stage M neuroblastoma patients. Oncotarget, 2015, 6, 13295-13308.	1.8	13
68	Dexamethasone Prophylaxis in Pediatric Open Heart Surgery Is Associated with Increased Blood Long Pentraxin PTX3: Potential Clinical Implications. Clinical and Developmental Immunology, 2011, 2011, 1-6.	3.3	11
69	The Role of HLA-Class Ib Molecules in Immune-Related Diseases, Tumors, and Infections 2016. Journal of Immunology Research, 2017, 2017, 1-2.	2.2	11
70	Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma. Journal of Immunology Research, 2018, 2018, 1-12.	2.2	11
71	Functional insights into nucleotide-metabolizing ectoenzymes expressed by bone marrow-resident cells in patients with multiple myeloma. Immunology Letters, 2019, 205, 40-50.	2.5	11
72	The Role of Extracellular Vesicles in the Progression of Human Neuroblastoma. International Journal of Molecular Sciences, 2021, 22, 3964.	4.1	11

#	Article	IF	Citations
73	Cytokine flexibility of early and differentiated memory T helper cells in juvenile idiopathic arthritis. Journal of Rheumatology, 2004, 31, 2048-54.	2.0	11
74	Soluble HLA-G modulates miRNA-210 and miRNA-451 expression in activated CD4+ T lymphocytes. International Immunology, 2013, 25, 279-285.	4.0	10
75	Soluble HLA-G and HLA-E Levels in Bone Marrow Plasma Samples Are Related to Disease Stage in Neuroblastoma Patients. Journal of Immunology Research, 2016, 2016, 1-6.	2.2	10
76	Levels of soluble CD27 in sera and synovial fluid and its expression on memory T cells in patients with juvenile idiopathic arthritides. Clinical and Experimental Rheumatology, 2002, 20, 863-6.	0.8	10
77	Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma. Oncolmmunology, 2018, 7, e1468953.	4.6	9
78	Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes. Cells, 2021, 10, 927.	4.1	8
79	Altered centrosomes in ataxia-telangiectasia cells and rapamycin-treated Chinese hamster cells. Environmental and Molecular Mutagenesis, 2005, 46, 164-173.	2.2	7
80	Expression of <i>FOXP3 </i> , <i>CD14 </i> , and <i>ARG1 </i> in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival. BioMed Research International, 2015, 2015, 1-10.	1.9	6
81	Impairment of lung function might be related to IL-10 and IFN- \hat{l}^3 defective production in allergic children. Immunology Letters, 2011, 140, 104-106.	2.5	5
82	Identification of Biochemical and Molecular Markers of Early Aging in Childhood Cancer Survivors. Cancers, 2021, 13, 5214.	3.7	5
83	The Role of HLA-Class Ib Molecules in Immune-Related Diseases, Tumors, and Infections. Journal of Immunology Research, 2014, 2014, 1-2.	2.2	4
84	Umbilical Cord Blood Transplantation: Should Perinatal Solid Cancer Become a Matter of Concern?. Journal of the National Cancer Institute, 2008, 100, 1822-1823.	6.3	2
85	Ciclesonide modulates in vitro allergen-driven activation of blood mononuclear cells and allergen-specific T-cell blasts. Immunology Letters, 2012, 141, 190-196.	2.5	2
86	miRNA expression profile of bone marrow resident cells from children with neuroblastoma is not significantly different from that of healthy children. Oncotarget, 2018, 9, 19014-19025.	1.8	2
87	Subcutaneous and sublingual immunotherapy and T regulatory cells: there is clinical relevance. Clinical and Experimental Allergy, 2010, 40, 1578-1579.	2.9	1
88	Molecular Determinants of Neuroblastoma. International Journal of Molecular Sciences, 2022, 23, 3751.	4.1	1
89	Bone Marrow Infiltration in Neuroblastoma: Characteristics of Infiltrating Cells and Role of the Microenvironment. , 0, , .		0